Curaleaf Holdings (CURA) introduced this week that it intends to launch an unsolicited take-over bid of its rival Aurora Hashish (ACB) in what would mark some of the consequential consolidation strikes in trade historical past.
On August 11, Curaleaf, now one of many largest hashish corporations on the earth by income, knowledgeable traders that it meant to make a proposal to buy all the issued and excellent shares in Aurora at US$4.00 per share.
“We imagine this mixture represents a win-win for Curaleaf and Aurora shareholders,” Boris Jordan, Chairman and Chief Government Officer of Curaleaf, mentioned of the provide.
Aurora, understandably, was extra cautious. Inside hours, Aurora responded to the announcement disputing Curaleaf’s account of their personal dealings and confirming its board would type a particular committee of unbiased administrators to weigh the proposal.
A modest price ticket
Curaleaf’s provide combines 0.3463 of a Curaleaf share and US$0.75 in money for every Aurora share, collectively value US$4.00 a share for the Edmonton-based medical hashish producer, a forty five% premium to Aurora’s 30-day volume-weighted common value of US$2.75.
Strip out the money sitting on Aurora’s personal stability sheet, and Curaleaf calculates the premium at 110%. Utilized to the 58.9 million Aurora shares on problem as of March 31, 2026, per the corporate’s most current SEC submitting, that values the bid at roughly US$236m on a basic-share foundation, a determine that will run larger as soon as excellent choices and warrants are counted.
That price ticket pales compared to among the landmark offers of the primary ‘inexperienced rush’. Aphria’s 2020 merger with Tilray was value roughly US$3.9bn, on the time creating what was billed because the world’s largest hashish firm by income.
Aurora’s personal 2018 buy of MedReleaf was reported to be value between US$2.5bn US$3.2bn, relying on the supply, whereas Curaleaf’s 2020 acquisition of Grassroots for US$875m additionally dwarfs its present bid for Aurora.
It’s, nevertheless, the primary time a number one hashish firm has taken a ‘hostile’ strategy to acquisition since Inexperienced Development Manufacturers’ failed 2019 hostile bid for Aphria.
On the time, this deal was value roughly CA$2.8bn earlier than it lapsed with out assembly the minimal tender situation. After the bid collapsed, Aphria selected a pleasant merger with Tilray.
It’s also illustrative of the dramatic evolution of the sector within the handful of years since these offers have been thought of commonplace.
Curaleaf’s roughly US$236m provide values Aurora at near 1x its CA$320.6m in fiscal 2026 income, transformed at round CA$1.40 to the US greenback.
Aurora’s personal buy of MedReleaf in 2018 priced the goal at roughly 66 instances its projected income, with hashish shares on the time generally buying and selling at multiples touching over 100.
Writing in Enterprise of Hashish earlier this 12 months, Sean McLean, CEO of PPS, argues that the hashish sector is artificially suppressed and can possible see a structural repricing as soon as tax and possession constraints ease.
Others imagine it’s merely an indication of maturation, and the results of classes discovered the laborious method from the preliminary hashish rush.
“Buyers are rather more disciplined and cautious about deploying capital into this sector now,” Philip Campbell, Chief Government Officer of Natural Dispatch, advised Enterprise of Hashish in June.
The European prize
Valuations apart, the importance of this deal lies within the pairs’ collective European property. Over the previous couple of years, North America’s as soon as booming shopper market has grow to be wildly aggressive, and largely commoditised.
Europe, in contrast, has seen speedy progress in its extra stringently regulated medical markets, and the most recent forecast from Prohibition Companions suggests medical hashish gross sales will greater than double by 2028.
Aurora
Aurora, one of many earliest movers within the European hashish market, is now one among many North American giants doubling down on the European alternative.
In its fiscal 2026 Q3 outcomes, printed in February, Aurora reported international medical hashish internet income at a then-record CA$76.2m for the quarter, up 12% year-on-year, pushed primarily by its positions in Germany and Poland.
This meant that earnings from its medical operations accounted for 81% of its income, and 95% of adjusted gross revenue. In This autumn, this rose to 91% of complete income, bringing the complete for the complete 12 months as much as 90%.
Alongside its ends in February, Aurora additionally confirmed it could successfully exit the buyer hashish markets in Canada from This autumn FY26 onwards, with CEO Miguel Martin telling BNN Bloomberg: “As we speak, we introduced additional concentrate on worldwide medical hashish, which has a lot stronger margins, a lot stronger progress, and an actual emphasis on science and genetics in regulated markets.”
That reallocation isn’t completed. Aurora remains to be winding down its Canadian shopper hashish and plant propagation companies in favour of its medical channels, having divested its 50.1% stake in propagation unit Bevo on February 17, 2026, with the remainder of the exit anticipated subsequent 12 months.
In January 2026, Aurora secured EU Group Plant Selection Rights overlaying the unique industrial management over each varieties throughout all 27 EU member states for 2 proprietary strains bred at its Aurora Coast facility in Canada, a transfer it mentioned would guarantee ‘high-quality, differentiated varieties can constantly attain sufferers and shoppers worldwide’
This was backed by a US$100m at-the-market fairness programme explicitly earmarked for ‘elevated cultivation capability and potential M&A.’
In Germany, its enterprise Pedanios, holds EU-GMP licensed manufacturing capability and launched localised digital platforms in Germany, the UK and Poland in February 2026.
Throughout its Q1 2027 earnings name, Martin mentioned Aurora holds ‘the primary market share place, supported by robust industrial execution’ in Poland, one of many quickest rising markets within the area. Equally, in Germany, the CEO advised traders that two ‘of our proprietary cultivars [are] persevering with to rank within the high 5 by gross sales’, whereas Aurora is one among solely three lively in-country producers of medical hashish holding a manufacturing and R&D license’.
Curaleaf
Curaleaf’s personal European operations are, equally, serving to prop up the wavering margins in North America.
Its full-year 2025 income of US$1.27b makes it the most important pureplay hashish firm on the earth by turnover. Nevertheless, this headline determine masks a 3rd consecutive 12 months of double-digit home value compression, main its administration to name 2025 ‘the trough.’
Conversely, Curaleaf Worldwide posted US$172.5m in income for the 12 months, up 63%, with This autumn alone up 65% year-on-year to an annualised run price above US$200m.
This was pushed by its German operations, the place Curaleaf is already the most important single provider, and the UK, the place Curaleaf Clinic held the highest market share by affected person rely throughout the quarter.
Past flower exports, Curaleaf’s CE-certified QMID inhalation machine, the primary of its type within the UK, is rising as a differentiator as France and Spain’s incoming medical frameworks favour standardised, device-led supply.
Curaleaf’s worldwide arm is presently dragging group EBITDA margins by 120 foundation factors, and the corporate posted a full-year internet lack of US$228m, with France and Turkey, its subsequent hoped-for contributors, not anticipated on-line till late 2026 and early 2027 respectively.
In February, it completed a US$500m personal placement of senior secured notes, which its group CEO Boris Jordan known as the most important bond providing the hashish sector has accomplished, pointing to institutional urge for food for the deal as an indication of how capital markets now view the trade.
That refinancing left Curaleaf with US$102m in money and, by its personal account, the pliability to pursue strategic acquisitions, the identical capital place now underpinning the bid for Aurora.
The mixed property
Jordan’s said rationale for the takeover bid means that combining ‘Curaleaf’s international distribution platform with Aurora’s main worldwide medical hashish franchise and EU-GMP cultivation and manufacturing capability’ would unlock ‘substantial value and income synergies’, set to complete a minimal of US$40m a 12 months.
The professional forma firm would carry trailing 12-month income of US$1.5b and adjusted EBITDA of US$350m, throughout a footprint spanning 17 nations.
In Europe particularly, that is much less about creating a brand new place than consolidating two present ones. Aurora’s number-one share in Poland, its EU-GMP manufacturing below Pedanios, and the Safari Flower Firm cultivation capability in Ontario would sit alongside Curaleaf’s standing as Germany’s largest single flower provider, its UK clinic community, and its personal EU-GMP amenities in Portugal, Spain and Canada. Mixed, the 2 corporations would maintain both outright management or a top-five product place in three of the continent’s most intently watched medical hashish markets.
Aurora’s shares rose 22% to US$3.48 on the day of the announcement, then added an extra 9.61% the next session to US$3.82, nonetheless under the US$4.00 headline provide, a niche that displays deal-completion uncertainty as a lot as any expectation of a sweetened bid.
Nevertheless, not everybody agrees this could be a ‘win, win’ for each corporations. Analysts at TD Cowen, Derek Lessard and Ryan Neal, wrote that the provide ‘doesn’t absolutely seize Aurora’s long-term intrinsic worth’, pointing to Aurora’s medical hashish management and genetics portfolio as causes the enterprise is value greater than Curaleaf is providing.
Aurora’s particular committee’s assessment is the subsequent milestone to observe, whereas analysts await a proper bid from Curaleaf.